# Jun Ma

Source: https://onco.cc/people/ma-jun/  
OnCo record `ma-jun` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Jun Ma is the world's leading nasopharyngeal carcinoma trialist, whose randomised studies define induction chemotherapy and immunotherapy for the disease.

## Summary

Jun Ma is Professor of Radiation Oncology and leads the nasopharyngeal carcinoma programme at Sun Yat-sen University Cancer Center in Guangzhou. He is the world's leading nasopharyngeal carcinoma trialist, and his randomised studies established gemcitabine plus cisplatin induction chemotherapy, defined the role of Epstein-Barr virus DNA in risk stratification and, with colleagues in JUPITER-02, tested PD-1 blockade in the disease. His publications include the trial of gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. His work, built on modern intensity-modulated radiotherapy, shapes international guidelines for this cancer.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Professor of Radiation Oncology; nasopharyngeal carcinoma programme, Sun Yat-sen University Cancer Center
- Specialisms: Nasopharyngeal carcinoma; Radiation oncology; Induction chemotherapy; EBV DNA

## Sources

- Sun Yat-sen University Cancer Center: https://www.sysucc.org.cn
- PubMed author search: https://pubmed.ncbi.nlm.nih.gov/?term=Ma%20J%5BAuthor%5D%20nasopharyngeal%20carcinoma%20Sun%20Yat-sen

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- technologies: [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- institutions: [Sun Yat-sen University Cancer Center](https://onco.cc/institutions/sysucc/)
- trials: [JUPITER-02](https://onco.cc/trials/jupiter-02/)

---
JSON: https://onco.cc/api/v1/entities/ma-jun.json